<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618706</url>
  </required_header>
  <id_info>
    <org_study_id>4-2018-0299</org_study_id>
    <nct_id>NCT03618706</nct_id>
  </id_info>
  <brief_title>Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer</brief_title>
  <official_title>A Phase II Trial of Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the effect of involved-field radiotherapy for recurrent
      ovarian cancer after primary standard treatment. We will investigate whether the addition of
      involved-field RT improves 2-year PFS in those patients than that of historical data (only
      with other standard salvage treatments as systemic chemotherapy ± maximum tumor resection).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2018</start_date>
  <completion_date type="Anticipated">May 9, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 9, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year progression-free survival (PFS)</measure>
    <time_frame>2 years after radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control of recurred lesions</measure>
    <time_frame>2 years after radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any other new recurrence events</measure>
    <time_frame>2 years after radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy-related complications</measure>
    <time_frame>2 years after radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy-free interval (The interval to delay the need for a new chemotherapy regimen for disease progression)</measure>
    <time_frame>2 years after radiotherapy</time_frame>
    <description>It means the interval between the last date performing the previous chemotherapy (before the start of involved-field radiotherapy) and the first date performing the new regimen of chemotherapy (for the disease failures after the involve-field radiotherapy). We want to measure this interval because we want to check the capability of involved-field radiotherapy to delay the need for the new regimen of chemotherapy for the progressive diseases.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">107</enrollment>
  <condition>Recurrent Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>involved-field RT + standard salvage treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving involved-field RT on recurred lesions + standard salvage treatment for recurrent ovarian cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Involved-field radiotherapy</intervention_name>
    <description>After the diagnosis of recurrences, patients will receive involved-field radiotherapy (gross tumor volume + margin) with any radiation dose scheme (≥45 Gy Biological Equivalent dose) as physician's discretion.</description>
    <arm_group_label>involved-field RT + standard salvage treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed ovarian carcinoma

          -  Patients who received &quot;standard treatment&quot; for each stage as a primary treatment

          -  No. of recurrent lesions:

        If, all in lung, or intra-abdominal or pelvis organs - ≤ 5 If, any in liver, bone, or
        spinal cord - ≤ 2

          -  Size of recurrent lesions ≤5 cm

          -  All recurrent lesions are available for involved-field radiotherapy

          -  Within 60 days before enrollment:

          -  Absolute neutrophil count ANC ≥ 500 / mm3

          -  Platelet ≥ 50,000 / mm3

          -  Hb ≥ 8.0 g / dl

          -  Good performance status (ECOG 0-1)

        Exclusion Criteria:

          -  Brain metastasis

          -  Diffuse peritoneal carcinomatosis

          -  Malignant pleural effusion

          -  History of previous salvage radiotherapy for recurrent lesions

          -  History of other malignancy or severe/unstable medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yong Bae Kim, MD, PhD</last_name>
    <phone>82-2228-8095</phone>
    <email>ybkim3@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YongBae Kim, MD</last_name>
      <phone>82-10-6256-2592</phone>
      <email>ybkim3@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>August 1, 2018</last_update_submitted>
  <last_update_submitted_qc>August 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

